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The national picture for COVID-19 is worsening with widespread and unchecked community spread:






D.C. is faring slightly better than most of the rest of the U.S., but trends are upward vs. peaking for
cases, hospitalizations, and deaths in the District. Especially in the next few days, beware the
Thanksgiving Mirage which will likely occur due to inconsistent holiday data collection.
The District remains in Phase II for now but is issuing modifications on 25NOV which restrict the
capacity for gatherings to <10 indoor and <25 outdoors. Hospital bed occupancy is at ~80%, ICU bed
occupancy is at 82%, and ventilator utilization is at ~40% of normal standard of care capacity.
A national analysis of ED visits by syndrome is showing an increasing trend in shortness of breath
( 2%) and coronavirus-like illness cases ( 3%) in the past two months
A high level of concern is present about the impact that Thanksgiving travel and gatherings may
present. The experience with Canadian Thanksgiving suggests that these fears are well founded.
A recent publication backing the interactive real-time COVID-19 Event Risk Assessment Planning
Tool website established that the risk of transmission during gatherings is heterogeneous in the U.S.
depending on size of gathering and geography. For example, a 10-person gathering this week in some
areas of the Midwest has a >90% risk of having at least one COVID-positive person present.

Vaccines are the top news stories this month with foci on their high efficacy in phase III trials, and
the extraordinary logistical requirements to effectively distribute and dispense them:









Unpublished reports from initial phase III analyses for three candidate vaccines (Pfizer, Moderna, and
AstraZeneca) are demonstrating up to 95% efficacy, but full details on safety and efficacy are
forthcoming. These will likely be reviewed expeditiously for FDA Emergency Use Authorization
approval.
The cold chain requirements for the Pfizer and Moderna vaccines will present an epic challenge and
limit the possibilities for distribution to remote areas. The AstraZeneca product, however, only
requires 36-46 F temperatures for safe storage and will likely be the go-to product for underserved
and under-resourced regions of the globe for that reason.
The social ramifications of mass vaccination will be hotly discussed in the coming weeks as
employers struggle with the decision to make vaccination mandatory, priorities for vaccination are
finalized, and great uncertainties remain about the public uptake of a pandemic vaccine.
It is highly likely that the ~20M healthcare workers in the U.S. will be prioritized for the earliest
tranches of vaccinations, along with other higher risk groups such as adults >65 (~50M), other essential
workers (~60M), and those with complex medical conditions (>100M)
If there was any question whether childhood vaccines are the mechanism providing an advantage for
children against COVID-19, the answer is likely no, as no cross-reacting antibodies were detectable in
recently immunized pediatric patients.
A NEJM article discusses using “no-fault compensation [for vaccine injury]” to increase some of
the risks for those potential administering the therapy, and to improve equitable access

Additional studies are better defining the epidemiology, risk factors, and morbidity of COVID-19:



The CDC updated its guidance for Risk Assessment and Work Restrictions for Healthcare Personnel
defining “prolonged close contact” from 15 minutes to any cumulative 15 minutes in a 24-hour period
Body Mass Index correlates with the risk of intubation or death, up to a relative risk of 1.6 for those
with class 3 obesity
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Patients with left ventricular dysfunction are likely at an increased risk of infection or death
In light of the recent reports of the zoonotic spread of COVID from minks to humans, and given the
millions of COVID‐19 cases worldwide and ongoing potential for further zoonotic and anthroponotic
viral transmission, further research and surveillance activities are needed to definitively determine the
role of animals in community transmission of SARS‐CoV‐2
Persistent fatigue during recovery is common (~52% at 10 weeks) and independent of severity of initial
infection
A case series of sailors on the U.S.S. Theodore Roosevelt showed that a quarter of the crew of ~5000
became infected, 50% asymptomatically, with 23 hospitalizations, 4 serious (ICU) cases, and 1 fatality
One healthcare system’s experience showed that of 1648 COVID-19 patients admitted to 38 hospitals,
24% died during hospitalization and 76% survived. Of 1250 patients discharged alive, 78% went home
whereas 12.6% were discharged to rehabilitation. By 60 days after discharge, an additional 84 patients
(6.7% of hospital survivors and 10.4% of ICU-treated hospital survivors) had died, bringing the overall
mortality rate for the cohort to 29.2%, and 63.5% for the 405 patients who received treatment in an
ICU. Within 60 days of discharge, 189 patients (15.1% of hospital survivors) were rehospitalized.
Ongoing surveillance for and epidemiologic monitoring of SARS-CoV-2 genetic diversity for
significant variants will be important in the coming months. For example, the “Spike 839Y variant”
spread rapidly in April in Portugal and has been detected in dozens of other countries, with yetunknown impact.
A case series from MGH in Boston did not demonstrate increased risk of COVID-19 infection in
patients receiving corticosteroid therapy, a practice some other researchers had recommended against.
A study from Wuhan demonstrated the power of quarantine as a tool to reduce community spread by
99% when it is effectively implemented
As previously reported, there is a growing body of evidence to suggest the risk caused by aerosol
transmission of COVID-19 is significantly lower than the risk caused by close contact, although there
is no question that genetic information from SARS-CoV-2 can be recovered from HVAC systems,
suggesting that the virus is likely able to travel further than close contact.
Temperature and humidity patterns such as diurnal temperatures (India), seasonality (Brazil), and
humidity (Europe) may be major contributors to regional COVID-19 transmission
Not surprisingly, a review of NHANES data in the U.S. found that 74% of the population has at least
one risk factor for severe COVID-19, such as obesity (41%), HTN (50%), with low-income individuals
and those with less education typically having more
In long-haul COVID-19 patients, 6% still have pulmonary function abnormality 3 months after
discharge, which did not vary by disease severity during hospitalization, and 86% patients had longterm abnormalities on chest CT
A non-peer reviewed study suggests the presence of long-term (>6 months) immunologic memory
after infection, which is great news for the potential of herd immunity

Pediatric and Obstetric information continues to evolve:





A study involving 250 urban adolescents from New South Wales quantifies what we’re all likely
feeling- there are increased anxiety and depressive symptoms, and decreased life satisfaction due to the
governmental restrictions
The University of Nevada found in a cross-sectional survey of students that a stay-at-home order
correlated with increased levels of depression and decreased levels of physical activity
Similarly, a Japanese study demonstrated a high prevalence of anhedonia, depression, and anxiety in
pregnant and postpartum women
A small study from Copenhagen found no increased fetal risk from low-severity COVID-19
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infections during the first trimester of pregnancy
JAMA Pediatrics published best practice for breastfeeding mothers during COVID-19- bottom line
the benefits outweigh the risks
A small retrospective cohort study from Wuhan found that COVID-19 infection is unlikely to cause
sterility or hypogonadism in males. Of interest, a study in Italy found more new cases of precocious
puberty in girls, potentially attributable to the environment of isolation, including increased BMI and
stress.
The Children’s Hospital Association and the American Academy of Pediatrics published a summary
of aggregated state data for pediatric patients from 49 jurisdictions
In a case series of children ages 4-12 years old in Europe with the MIS-C syndrome, 65% had evidence
of past or current COVID-19 infection (lower than other studies) and 93% had cardiac involvement with
elevated inflammatory markers—important to screen for this
Children appear to have not just have chilblain-like cutaneous manifestations of COVID-19 as we have
previously reported, but a new report describes other skin manifestations such as urticaria and
erythema multiforme as well. These skin findings are not limited to children, either, based on a metaanalysis of 86 studies of children and adults that found chilblain-like lesions (52%), erythematous
maculopapular rashes (13%), and viral exanthems (8%) are common findings, and may be predictive.
A study from China conducted a systemic review of 32 publications on the outcomes of COVID-19 n
pregnancy. Vertical transmission was extremely low for mothers with COVID-19, however premature
birth was common at 36%.

Some interesting progress has been made with diagnostics and therapeutics:
 A study conducted in New York indicated that SARS-CoV-2 genomic load (viral load) trends with
clinical status, and may serve as a predictive tool for patient management
 An RCT with almost 500 hospitalized adults did not support the use of hydroxychloroquine for
treatment of COVID-19
 In a preliminary RCT, adult outpatients with symptomatic COVID-19 treated with fluvoxamine, had
a lower likelihood of clinical deterioration over 15 days
 The FDA issued EUA use guidelines for bamlanivimab for the treatment of COVID-19
 Point of care ultrasound showed the ability to monitor the evolution of severe COVID-19 pneumonia
after discharge, supporting its integration in predictive models of residual lung injury
 As part of the hyper-inflammatory state of some COVID-19 infections, there is likely an increased
susceptibility to systemic thromboembolic complications, suggesting a role for thromboembolism
prophylaxis. Another study highlighted that anticoagulation plans should be personalized according to
risk and disease course. Lastly, a small Mayo Clinic case-control study of post-mortem COVID-19
patients found COVID-19 patients were significantly more likely to have fibrin microthrombi.
 Also from Mayo, a meta-analysis and consensus report that anticoagulation provided no mortality
benefit over thromboprophylaxis, independent of co-morbidities or disease severity. More adverse
events were observed with therapeutic AC.
 GW investigators reported a retrospective analysis of 400 hospitalized COVID patients demonstrated
that therapeutic anticoagulation provided no mortality benefit over thromboprophylaxis, independent of
co-morbidities or disease severity, with greater risk of adverse events
 A very interesting modeling analysis explored the use of the U.S. Postal Service as an avenue for
testing. >94% of Americans could travel less than 7 miles to a post office facility for COVID-19
testing in a scenario that would provide consistence and ease of and access to testing
 A retrospective study of 4000 ICU patients in the U.S. revealed an estimated 30-day mortality of 27.5%
in patients treated with tocilizumab, compared to 37.1% in patients without tocilizumab, suggesting the
3








drug's benefit in treatment of critically ill COVID-19 patients. Other studies have found less convincing
results with regard to 30-day mortality.
Rintatolimod may be useful as a potential therapeutic agent in patients with COVID-19 "long-hauler"
post-viral syndrome to reduce lingering brain-fog and fatigue based on phase III research in patient
with chronic fatigue syndrome
How predictive is RT-PCR testing during the evolution of COVID-19 illness in the symptomatic
patient? A 32-study systematic review found the highest rate of virus detection (89%) in the first 4
days, dropping to 54% after 10 days.
The discussion on remdesivir continues- this review article describes a better 14-day mortality profile,
clinical recovery, and discharge rate on the medication. Overall clinical improvement and clinical
recovery were earlier among the treated group, but longer-course therapy showed more adverse
outcomes a than 5-day course with no significant benefits
Duke University produced a surgical clinical decision support tool which considers urgency of proposed
surgical procedures, and the need for ICU space, ventilator support, and recovery in an SNF
Because you were wondering, polyester swabs had decreased performance compared to foam swabs
during nasal COVID-19 testing

Some additional highlights:









Where do all the other sick people go during a pandemic? A recent study at the Stanford and Cornell
health care systems analyzed the presentation rates for five emergencies and found decreased incidence of
acute myocardial infarction, non-traumatic subarachnoid hemorrhage, and ischemic stroke cases in both
centers, a decrease in appendicitis cases in New York, and no changes in ectopic pregnancy cases at
either center
In cold climates, forehead temperatures upon entering a facility where temperature screening takes
place may take up to one hour to stabilize. As such, in many geographic regions, temperature
screening is likely of limited value. Act surprised.
A recent academic presentation at the virtual American College of Emergency Physicians
conference reported that N95 masks may start to fail after two shifts
The WHO has updated its technical guidelines for PPE use in COVID-19, unfortunately without
“track changes or updates” information that would greatly increase the utility of this document
Cellphone metadata is useful for tracking the spread of COVID-19, explaining inequities, and
informing reopening in a Stanford University report
Dr. Fauci et al wrote a commentary on the urgent need for early treatment options for COVID-19
In an interesting analysis on the quality of literature, a “case control” Swiss study compared 155
COVID-19 related publications in NEJM, Lancet, and JAMA and found that pandemic literature
had lower levels of evidence and less favorable quality scores

This edition of the COVID-19 Intelligence Report was produced by Dr. Andy Garrett with support from
the Himmelfarb Librarian team and the entire GW Intelligence Unit led by Dr. Lawrence “Bopper”
Deyton.
Feedback and any special requests should go to: ldeyton@gwu.edu. Stay safe and informed. For past editions
of the GW Intelligence Report, please visit the Himmelfarb library site.
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